This article is more than 5 years old. Information may no longer be current.

STAAR Surgical sales decrease in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MONROVIA, Calif. — Net sales in the third quarter of 2005 fell 4% for STAAR Surgical, to $11.6 million, compared with the same quarter in the previous year, the company announced in a press release. The company said the overall decrease was due to a 19% decrease in U.S. IOL sales.

STAAR noted that the U.S. sales decline was “primarily due” to a Food and Drug Administration letter, received by the company in July, indicating that STAAR was still not in compliance with quality systems regulations. The decrease in U.S. IOL sales was partially offset by an 8% increase in international sales, the release said.

During the third quarter, international sales of the Visian ICL phakic IOL increased 14% compared with sales of the lens in the third quarter of 2004. International sales of STAAR’s preloaded silicone IOL increased 66% compared with the year-ago quarter, according to the company.

Net losses for the third quarter of 2005 were $3.3 million, up from $2.3 million in the third quarter of 2004, the release noted.